Viekira Pak
Viekira Pak
Viekira Pak (pronounced: vie-KEE-ra pak) is a prescription medication used in the treatment of chronic hepatitis C. It is a combination of four different medications: ombitasvir, paritaprevir, ritonavir, and dasabuvir.
Etymology
The name "Viekira Pak" is a brand name, and does not have a known etymology. It is a product of AbbVie Inc., a global biopharmaceutical company.
Usage
Viekira Pak is used to treat chronic hepatitis C virus (HCV) genotype 1 infection, including those with compensated cirrhosis. It is used in combination with or without ribavirin, another antiviral medication.
Mechanism of Action
Each component of Viekira Pak works in a different way to stop the hepatitis C virus from multiplying. Ombitasvir, paritaprevir, and dasabuvir directly inhibit the replication of the HCV RNA, while ritonavir enhances the level of paritaprevir by inhibiting its metabolism.
Side Effects
Common side effects of Viekira Pak include fatigue, nausea, itching, skin reactions, insomnia, and weakness. Severe side effects can include liver failure, especially in people with advanced liver disease.
Related Terms
External links
- Medical encyclopedia article on Viekira Pak
- Wikipedia's article - Viekira Pak
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski